Related Experiment Video
Updated: Nov 22, 2025
08:41
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
3.1K
Early Returns on Small Molecule Therapeutics for SARS-CoV-2
1Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 25 Shattuck Street, Boston, Massachusetts 02115, United States.
ACS Infectious Diseases
|January 8, 2021
Summary
The COVID-19 pandemic spurred rapid drug discovery for SARS-CoV-2. This study evaluates medicinal chemistry and computational methods to identify efficient therapeutic strategies for future pandemics.
Area of Science:
- Drug discovery and development
- Infectious disease research
- Medicinal chemistry
Background:
- The COVID-19 pandemic necessitated urgent development of therapeutics against SARS-CoV-2.
- Extensive research employed traditional medicinal chemistry, drug repurposing, and computational strategies.
Purpose of the Study:
- To assess the efficiency of various chemical and testing approaches in identifying potential SARS-CoV-2 treatments.
- To inform preparedness strategies for future pandemic responses.
Main Methods:
- Review of medicinal chemistry efforts.
- Analysis of drug repurposing initiatives.
- Evaluation of computational approaches in drug discovery.
Main Results:
- Identification of key chemical strategies and testing methodologies.
- Assessment of the speed and success rates of different approaches.
- Insights into the most efficient pathways for small molecule progression.
Conclusions:
- The rapid progression of small molecules highlights the success of integrated drug discovery efforts.
- Lessons learned can optimize responses to future viral pandemics.
- Efficient therapeutic identification is crucial for global health security.
